Skip to main content
Equibles
ADGM logo

ADGM · Adagio Medical Holdings, Inc.

Track ADGM — free

Use ADGM with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about ADGM

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$0.52 0.00 (-0.33%) At close · Aug 27
Going-concern doubt — flagged Aug 11, 2026

Substantial doubt about the company's ability to continue as a going concern.

“We do not believe our existing cash and cash equivalents will be sufficient to fund operations for at least the next twelve months from the issuance date of the condensed consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q. We believe that this raises substantial doubt about our ability to continue as a going concern.”
View the 10-Q filed Aug 11, 2026
Market Cap
$11.59M
Shares
22.21M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$0.52 Open$0.54 Day$0.52–0.55 52W close$0.38–2.36 Avg vol 30d17.1M Short int325K · 1.5% float · 1.0d Short vol37% Last earningsMar 27, 2026 DataAug 2024–Aug 2026 Filing10-Q · Aug 11

Up next

FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed Aug 11, 2026

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Strong Sell Momentum Weak Sentiment Neutral Fundamentals Weak Quant / Vol Very High
Market backdrop VIX 14.5 · calm Equity put/call 0.39
Technical
price trend
Strong Sell
50 / 200-day cross No cross
Price vs 200-day avg −42%
below
Price vs 50-day avg −13%
below
RSI (14) 39
neutral
MACD trend Negative
52-week position 7%
near low
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Weak
1-month return +39%
trailing
6-month return −47%
trailing
YTD return −50%
this year
Relative strength −61%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow Accumulating
+4% holders QoQ · +4 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
1.47% of float · ▲ +446.4% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
24 holders — near 2-yr high, broad support
Squeeze score 42
elevated · 0–100
Fundamentals
Weak
Revenue growth −100%
Y/Y
EPS growth +97%
Y/Y
Free cash flow $-19.4M
Balance sheet $3.9M
net debt
Quant / Vol
risk profile
Very High
Volatility 133%
annualized · 1-yr
Max drawdown −84%
past year
ATR 15.5%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Strong Sell
4 · 3 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−42% Bearish
Price vs 50-day avg
−13% Bearish
RSI (14)
39 Neutral
MACD trend
Negative Bearish
52-week position
7% Bearish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow Accumulating
+4% holders QoQ · +4 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
1.47% of float · ▲ +446.4% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
24 holders — near 2-yr high, broad support
Price context
position in its 52-week range
Range low $0 Now $1 · 7% Range high $2
vs 200-day avg -42% vs 50-day avg -13%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
FULCRUM-VT acute effectiveness 97% FY2025 —
FULCRUM-VT trial enrollment 209 FY2025 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Medical Devices — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
ADGM
Adagio Medical Holdings, Inc.
this stock
$11.59M -50.0% — — 1.5%
ABT
Abbott Laboratories
 $198.74B -10.9% +5.7% 32.0 1.2%
SYK
Stryker Corp
 $126.45B -8.4% +11.2% 34.2 1.8%
MDT
Medtronic plc
 $117.57B -6.3% +8.4% 24.6 1.1%
BSX
Boston Scientific Corp
 $68.44B -51.1% +12.5% 19.1 1.9%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
24
% held
67.9%
Net QoQ
-586.0K sh
Top holder
PERCEPTIVE ADVISORS LLC
Held Float
View
Held by Funds
Fund positions
5
View
Short & Settlement
Short Interest Rising
Shares short
325.4K
Days to cover
1.0d
Change
+265.9K sh
View
Short Volume
Short vol %
37%
As of
Aug 27, 2026
Short Total
View
Fails to Deliver
FTD shares
190
Value
$129
As of
Jun 23, 2026
View
Off-Exchange
Off-exchange %
48.2%
Week of
Jul 20, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$0
Net income (FY)
$-25.1M
EPS diluted
$-1.51
View
Filings
SEC Filings
Latest
8-K
Filed
Aug 14, 2026
This year
16
View
Exempt Offerings
Offering
$49.8M
Filed
Oct 29, 2025
View
Earnings & Events
Earnings Calls
Last call
Mar 27, 2026
View

Performance

5D 20D 120D MTD YTD
ADGM -17.9% +38.8% -46.8% +37.7% -50.0%
SPY +1.1% +4.0% +14.7% +3.2% +13.1%
vs SPY -19.0% +34.8% -61.4% +34.4% -63.1%
Key facts CIK 2006986 CUSIP 00534B100 13F (30d) 24 filings 23 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)